In the Memorial Sloan Kettering Cancer Center (MSKCC) primary prostate cancer cohort3, patients with both PTEN loss and FOXP1 loss had significantly worse biochemical recurrence rates than those with no loss, as determined by Cox regression (hazard ratio, HR, 4.56; 95% confidence interval, CI, 2.02, 10.26; P < 0.001; Supplementary Table 3, Fig. 4a). Here, FOXP1 is linked to prostate carcinoma.